Annandale, VA; June 23, 2021
Fight Against COVID-19 Continues with a New Clinical Trial
The leaders of the Clinical Alliance for Research and Education-Infectious Diseases (CARE-ID) would like to express their extreme gratitude to its volunteer participants in the Pfizer COVID-19 vaccine clinical trial. These volunteers’ contributions of time and consistent attention to detailed follow-ups helped lead to the Emergency Use Authorization (EUA) for one of the three COVID-19 vaccines in record time. The delivery of these vaccines has, in turn, substantially reduced new infections and created a pathway back to more normal lives.
“Our Pfizer vaccine study participants have and continue to assist in creating essential data on the durability and length of antibody protection post-vaccination. This effort is vital to adding to the understanding of how the virus and the vaccine behave over longer periods of time”, stated Executive Director, Steve Poretz. “To this end, we can begin to look at using this data to set out on a new Pfizer vaccine clinical trial to evaluate whether a booster (3rd dose) will be needed.”
Study participants who initially received the active vaccine (not the placebo) will be invited to enroll in the upcoming booster study. This will be conducted on a smaller scale with limits on how many participants can enroll.